(AZN) AstraZeneca - Ratings and Ratios

Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US0463531089

Cancer, Cardiovascular, Respiratory, Rare Diseases, Vaccines

AZN EPS (Earnings per Share)

EPS (Earnings per Share) of AZN over the last years for every Quarter: "2020-03": 0.3, "2020-06": 0.29, "2020-09": 0.25, "2020-12": 0.39, "2021-03": 0.59, "2021-06": 0.21, "2021-09": -0.55, "2021-12": -0.12, "2022-03": 0.12, "2022-06": 0.12, "2022-09": 0.53, "2022-12": 0.29, "2023-03": 0.58, "2023-06": 0.58, "2023-09": 0.44, "2023-12": 0.31, "2024-03": 0.7, "2024-06": 0.62, "2024-09": 0.46, "2024-12": 0.48, "2025-03": 0.93,

AZN Revenue

Revenue of AZN over the last years for every Quarter: 2020-03: 6354, 2020-06: 6275, 2020-09: 6578, 2020-12: 7410, 2021-03: 7320, 2021-06: 8220, 2021-09: 9866, 2021-12: 12011, 2022-03: 11390, 2022-06: 10771, 2022-09: 10982, 2022-12: 11207, 2023-03: 10879, 2023-06: 11416, 2023-09: 11492, 2023-12: 12024, 2024-03: 12679, 2024-06: 12938, 2024-09: 13565, 2024-12: 14891, 2025-03: 13588,

Description: AZN AstraZeneca

AstraZeneca PLC is a leading biopharmaceutical company with a diverse portfolio of prescription medicines across various therapeutic areas, including oncology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and rare diseases. The companys product pipeline is robust, with a range of established brands such as Tagrisso, Imfinzi, and Farxiga, as well as newer additions like Enhertu and Ultomiris.

From a strategic perspective, AstraZeneca has demonstrated a commitment to innovation through partnerships and collaborations, including a notable agreement with Tempus to develop a multimodal foundation model in oncology. Additionally, the companys collaboration with IonQ, Inc. to leverage quantum computing in computational chemistry workflow highlights its willingness to explore cutting-edge technologies. Key Performance Indicators (KPIs) such as Research and Development (R&D) expenditure as a percentage of revenue, and the success rate of its pipeline candidates, will be crucial in assessing the companys long-term growth prospects.

AstraZenecas global presence, with operations in the United Kingdom, the United States, Europe, and Asia, positions it well to capitalize on emerging opportunities in the biopharmaceutical market. The companys ability to serve primary and specialty care physicians through distributors and local representative offices is a key strength. To further evaluate the companys performance, metrics such as revenue growth rate, operating margin, and return on equity (RoE) of 19.18% will be closely monitored.

From a valuation perspective, AstraZenecas Price-to-Earnings (P/E) ratio of 27.89 and Forward P/E of 15.41 suggest a relatively stable valuation. The companys Market Capitalization of $215.9 billion USD underscores its significant presence in the global biopharmaceutical market. To gain a deeper understanding of the companys stock performance, metrics such as dividend yield, beta, and trading volume will be analyzed in conjunction with the provided technical data.

Additional Sources for AZN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle

AZN Stock Overview

Market Cap in USD 215,915m
Sector Healthcare
Industry Drug Manufacturers - General
GiC Sub-Industry Pharmaceuticals
IPO / Inception 1993-05-12

AZN Stock Ratings

Growth Rating 30.5
Fundamental 73.8
Dividend Rating 46.5
Rel. Strength -1.19
Analysts 4.42 of 5
Fair Price Momentum 67.42 USD
Fair Price DCF 61.75 USD

AZN Dividends

Dividend Yield 12m 2.17%
Yield on Cost 5y 2.92%
Annual Growth 5y 1.19%
Payout Consistency 96.4%
Payout Ratio 44.7%

AZN Growth Ratios

Growth Correlation 3m 35.1%
Growth Correlation 12m -42.9%
Growth Correlation 5y 88.4%
CAGR 5y 5.77%
CAGR/Max DD 5y 0.21
Sharpe Ratio 12m 0.93
Alpha -17.95
Beta 0.235
Volatility 23.40%
Current Volume 3698.7k
Average Volume 20d 3687.4k
Stop Loss 67.2 (-3%)
What is the price of AZN shares?
As of July 19, 2025, the stock is trading at USD 69.26 with a total of 3,698,651 shares traded.
Over the past week, the price has changed by -3.55%, over one month by -2.41%, over three months by +2.47% and over the past year by -11.41%.
Is AstraZeneca a good stock to buy?
Yes, based on ValueRay´s Fundamental Analyses, AstraZeneca (NASDAQ:AZN) is currently (July 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 73.81 and therefor a positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of AZN is around 67.42 USD . This means that AZN is currently overvalued and has a potential downside of -2.66%.
Is AZN a buy, sell or hold?
AstraZeneca has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy AZN.
  • Strong Buy: 6
  • Buy: 5
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecasts for AZN share price target?
According to our own proprietary Forecast Model, AZN AstraZeneca will be worth about 73 in July 2026. The stock is currently trading at 69.26. This means that the stock has a potential upside of +5.33%.
Issuer Target Up/Down from current
Wallstreet Target Price 84.2 21.5%
Analysts Target Price 84.2 21.5%
ValueRay Target Price 73 5.3%